|
1
|
Hoffman PC, Cohen EE, Masters GA, et al:
Carboplatin plus vinorelbine with concomitant radiation therapy in
advanced non-small cell lung cancer: a phase I study. Lung Cancer.
38:65–71. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okudela K, Woo T and Kitamura H: KRAS gene
mutations in lung cancer: particulars established and issues
unresolved. Pathol Int. 60:651–660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Woo T, Okudela K, Yazawa T, et al:
Prognostic value of KRAS mutations and Ki-67 expression in stage I
lung adenocarcinomas. Lung Cancer. 65:355–362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okudela K, Yazawa T, Ishii J, et al:
Down-regulation of FXYD3 expression in human lung cancers: its
mechanism and potential role in carcinogenesis. Am J Pathol.
175:2646–2656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Eijk R, Licht J, Schrumpf M, et al:
Rapid KRAS, EGFR, BRAF and PIK3CA
mutation analysis of fine needle aspirates from non-small-cell lung
cancer using allele-specific qPCR. PLoS One. 6:e177912011.
|
|
8
|
Xu J, He J, Yang H, et al: Somatic
mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients
with non-small cell lung cancer. Cancer Biomark. 10:63–69.
2012.PubMed/NCBI
|
|
9
|
Cozens AL, Yezzi MJ, Kunzelmann K, et al:
CFTR expression and chloride secretion in polarized immortal human
bronchial epithelial cells. Am J Respir Cell Mol Biol. 10:38–47.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yazawa T, Kamma H, Fujiwara M, et al: Lack
of class II transactivator causes severe deficiency of HLA-DR
expression in small cell lung cancer. J Pathol. 187:191–199. 1999.
View Article : Google Scholar
|
|
11
|
Okudela K, Yazawa T, Suzuki T, Sugimura H
and Kitamura H: Role of 3′-phosphoinositides in oncogenic
KRAS-induced modulation of shape and motility of airway epithelial
cells. Pathol Int. 59:28–37. 2009.
|
|
12
|
Okudela K, Suzuki M, Kageyama S, et al:
PIK3CA mutation and amplification in human lung cancer.
Pathol Int. 57:664–671. 2007. View Article : Google Scholar
|
|
13
|
Okudela K, Yazawa T, Woo T, et al:
Down-regulation of DUSP6 expression in lung cancer: its mechanism
and potential role in carcinogenesis. Am J Pathol. 175:867–881.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valastyan S, Reinhardt F, Benaich N, et
al: A pleiotropically acting microRNA, miR-31, inhibits breast
cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Augoff K, Das M, Bialkowska K, McCue B,
Plow EF and Sossey-Alaoui K: miR-31 is a broad regulator of
β1-integrin expression and function in cancer cells. Mol Cancer
Res. 9:1500–1508. 2011.
|
|
16
|
Zhang Y, Guo J, Li D, et al:
Down-regulation of miR-31 expression in gastric cancer tissues and
its clinical significance. Med Oncol. 27:685–689. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cottonham CL, Kaneko S and Xu L: miR-21
and miR-31 converge on TIAM1 to regulate migration and invasion of
colon carcinoma cells. J Biol Chem. 285:35293–35302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slaby O, Svoboda M, Fabian P, et al:
Altered expression of miR-21, miR-31, miR-143 and miR-145 is
related to clinicopathologic features of colorectal cancer.
Oncology. 72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guan P, Yin Z, Li X, Wu W and Zhou B:
Meta-analysis of human lung cancer microRNA expression profiling
studies comparing cancer tissues with normal tissues. J Exp Clin
Cancer Res. 31:542012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jang JS, Jeon HS, Sun Z, et al: Increased
miR-708 expression in NSCLC and its association with poor survival
in lung adenocarcinoma from never smokers. Clin Cancer Res.
18:3658–3667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao W, Yu Y, Cao H, et al: Deregulated
expression of miR-21, miR-143 and miR-181a in non small cell lung
cancer is related to clinicopathologic characteristics or patient
prognosis. Biomed Pharmacother. 64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Võsa U, Vooder T, Kolde R, et al:
Identification of miR-374a as a prognostic marker for survival in
patients with early-stage nonsmall cell lung cancer. Genes
Chromosomes Cancer. 50:812–822. 2011.PubMed/NCBI
|
|
23
|
Xing L, Todd NW, Yu L, Fang H and Jiang F:
Early detection of squamous cell lung cancer in sputum by a panel
of microRNA markers. Mod Pathol. 23:1157–1164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu L, Todd NW, Xing L, et al: Early
detection of lung adenocarcinoma in sputum by a panel of microRNA
markers. Int J Cancer. 127:2870–2878. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan X, Qin W, Zhang L, et al: A 5-microRNA
signature for lung squamous cell carcinoma diagnosis and hsa-miR-31
for prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meng W, Ye Z, Cui R, et al: MicroRNA-31
predicts the presence of lymph node metastases and survival in lung
adenocarcinoma patients. Clin Cancer Res. 19:5423–5433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duan L, Yang G, Zhang R, Feng L and Xu C:
Advancement in the research on vascular endothelial growth
inhibitor (VEGI). Target Oncol. 7:87–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
